Biotech

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Interviews CEO Steven Lydeamore

🕔4/16/2019 10:53:59 AM

While in Sydney earlier this month, Anatara Lifesciences (ASX:ANR) CEO Steve Lydeamore sat down with Stuart Roberts at Pitt Street Research, one of Australia's most experienced providers of equity research for ASX-listed small and mid cap companies.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔4/11/2019 10:48:52 AM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 March, 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Morgans Financial Limited Interviews CEO Steven Lydeamore

🕔3/29/2019 9:58:35 AM

While in Brisbane this week, Anatara Lifesciences CEO Steve Lydeamore (ASX:ANR) sat down with Scott Power, Senior Analyst at Morgans Financial Limited, Australia's largest national full-service retail stockbroking and wealth management network.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product

🕔3/22/2019 1:03:12 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔3/19/2019 9:29:24 AM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report

🕔3/19/2019 9:13:38 AM

Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Read Full Article

Regeneus Ltd (ASX:RGS) Half-Year Report

🕔3/1/2019 8:08:49 AM

Regeneus (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing a portfolio of novel cell-based therapies targeting significant unmet medical needs in human and animal health, with an initial focus on osteoarthritis, neuropathic pain and dermatology. The Company's product pipeline is underpinned by proprietary stem cell technologies.

Read Full Article